适应性抗癌免疫的线粒体检查点。

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2023-10-16 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2271693

Oliver Kepp, Peng Liu, Guido Kroemer, Lorenzo Galluzzi

引用次数: 0

摘要

BCL2有力地保持线粒体的完整性，从而抑制几种细胞类型的先天免疫信号传导和凋亡细胞死亡。在这里，我们评论了我们最近的数据，这些数据表明BCL2也限制了树突细胞引发适应性免疫反应的能力，为线粒体免疫检查点的普遍免疫抑制功能提供了支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A mitochondrial checkpoint to adaptive anticancer immunity.

查看原文本刊更多论文

A mitochondrial checkpoint to adaptive anticancer immunity.

BCL2 robustly preserves mitochondrial integrity, hence inhibiting innate immune signaling and apoptotic cell death in several cell types. Here, we comment on our recent data demonstrating that BCL2 also limits the ability of dendritic cells to elicit adaptive immune responses, lending support to a universal immunosuppressive function for the mitochondrial immune checkpoint.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.